Highlights of the Comparative Analysis
The management of central precocious puberty (CPP) has seen a significant shift toward long-acting formulations to improve patient quality of life. The recent UK multicentre retrospective cohort study provides several critical insights for clinicians:
1. Clinical Equivalence: The 24-weekly administration of Decapeptyl SR (22.5 mg) provides suppression of the hypothalamic-pituitary-gonadal (HPG) axis equivalent to the traditional 12-weekly (11.25 mg) regimen.
2. Stable Anthropometrics: No significant differences were observed in height velocity, body mass index (BMI) SDS, or Tanner staging progression between the two groups.
3. Patient Preference: 100% of patients and families who expressed a preference favored the 24-weekly schedule, citing reduced injection frequency and less disruption to daily life.
4. Safety and Tolerability: Both regimens were well-tolerated, with no new safety signals identified for the longer-acting preparation.
Introduction: The Evolving Landscape of CPP Management
Central precocious puberty (CPP) is characterized by the premature activation of the hypothalamic-pituitary-gonadal (HPG) axis before the age of 8 in girls and 9 in boys. If left untreated, the early exposure to sex steroids leads to accelerated bone maturation, premature epiphyseal fusion, and a significant reduction in final adult height, alongside potential psychosocial distress. For decades, gonadotropin-releasing hormone analogues (GnRHa) have remained the gold standard of care. By providing continuous stimulation to GnRH receptors, these agents paradoxically desensitize the pituitary gland, leading to the suppression of luteinising hormone (LH) and follicle-stimulating hormone (FSH) secretion.
Traditionally, GnRHa treatments required monthly or 12-weekly injections. However, the burden of frequent clinical visits and painful intramuscular or subcutaneous injections can negatively impact treatment adherence and patient well-being, particularly in a pediatric population. The introduction of 24-weekly (6-month) formulations represents a significant milestone in pediatric endocrinology, aiming to maintain therapeutic efficacy while minimizing the treatment burden. This study represents the first major comparative analysis to establish clinical equivalence between these two regimens within a UK-based cohort.
Study Methodology: A Robust Multicentre UK Evaluation
This study employed a retrospective cohort design, drawing data from three major tertiary pediatric endocrinology centers in the United Kingdom: the Royal London Hospital, Sheffield Children’s Hospital, and the Royal Victoria Infirmary. The inclusion period spanned over 16 years (2008–2024), providing a comprehensive view of clinical practices and longitudinal outcomes.
Participant Selection and Cohort Characteristics
A total of 247 patients were initially reviewed, with 164 meeting the strict eligibility criteria for final analysis. The cohort was predominantly female (220 girls vs. 27 boys), which aligns with the known epidemiological distribution of CPP. Patients were divided into two primary cohorts: Group 1 (n=69) received Decapeptyl SR 11.25 mg every 12 weeks, and Group 2 (n=95) received Decapeptyl SR 22.5 mg every 24 weeks.
Intervention and Monitoring Protocols
Baseline clinical assessments included chronological age, bone age, Tanner staging, and anthropometric measurements (height, weight, BMI). Biochemical monitoring involved measuring peak or basal LH and FSH levels, as well as sex steroid concentrations (estradiol in girls, testosterone in boys). Follow-up assessments were conducted according to standard clinical practice at each participating center, typically every 3 to 6 months. The primary endpoint was the successful suppression of the HPG axis, defined by clinical and biochemical stability.
Primary and Secondary Outcomes: Establishing Clinical Equivalence
Biochemical Suppression of the HPG Axis
The fundamental goal of GnRHa therapy is the maintenance of prepubertal hormone levels. The study found that both the 12-weekly and 24-weekly regimens achieved effective HPG axis suppression. There were no statistically significant differences in the median concentrations of LH or FSH between the two groups during the follow-up period. Furthermore, sex steroid concentrations remained within the prepubertal range for the vast majority of participants in both cohorts, confirming that the 24-weekly dose of 22.5 mg provides sufficient sustained release of Triptorelin to prevent breakthrough pubertal activation.
Clinical Progression and Anthropometric Stability
Beyond biochemistry, clinical markers of pubertal progression are vital indicators of treatment success. Height velocity (HV), a key metric in assessing the efficacy of CPP treatment, showed comparable deceleration in both groups, indicating successful prevention of premature growth plate closure. BMI SDS remained stable, addressing concerns that longer-acting GnRHa formulations might contribute to excessive weight gain. Tanner staging remained either stable or regressed in most patients, with no significant differences in the rate of pubertal progression between the 12-weekly and 24-weekly cohorts.
Patient Experience and Tolerability
One of the most compelling findings of the study was the qualitative data regarding patient and caregiver preference. In an era of patient-centered medicine, the reduction of medical interventions is a high priority for pediatric populations. Among the subset of patients who provided feedback on their preference, 100% preferred the 24-weekly regimen. The primary reasons cited included fewer needle-related traumas, reduced time away from school, and fewer hospital visits for caregivers.
In terms of safety, the 24-weekly preparation demonstrated a profile identical to the 12-weekly version. Local injection site reactions were minimal and transient, and no systemic adverse events were reported that necessitated treatment discontinuation. This reinforces the safety of higher-concentration, sustained-release formulations in children as young as six years old.
Expert Commentary: Shifting the Paradigm toward Long-Acting Formulations
The results of this multicentre study have significant implications for the standard of care in CPP. The clinical equivalence established here suggests that the 24-weekly regimen could—and perhaps should—become the preferred option for many patients.
Adherence and Psychological Impact
In chronic pediatric conditions, treatment fatigue is a well-documented phenomenon. By halving the number of required injections per year, the 24-weekly regimen likely improves long-term adherence, which is critical for ensuring optimal final adult height. Furthermore, for children with needle phobia or sensory sensitivities, the reduction in procedure frequency can significantly reduce the psychological burden associated with their diagnosis.
Resource Utilization and Health Economics
From a health systems perspective, the 24-weekly regimen offers potential cost savings. While the unit cost of the 22.5 mg formulation may be higher than the 11.25 mg dose, the overall reduction in clinical appointments, nursing time for administration, and administrative overheads for scheduling represents a significant benefit to the NHS and similar healthcare systems. Moreover, reducing the frequency of monitoring, provided the HPG axis remains stable, allows for more efficient use of specialist pediatric endocrinology resources.
Conclusion: A Validated Step Forward in Pediatric Endocrinology
This UK multicentre retrospective cohort study successfully demonstrates that 24-weekly Decapeptyl SR is both efficacious and well-tolerated for the management of central precocious puberty. By achieving biochemical and clinical outcomes comparable to the 12-weekly regimen, the 24-weekly formulation provides a robust alternative that significantly enhances patient and family satisfaction.
Clinicians can confidently transition appropriate patients to the 24-weekly schedule, knowing that HPG axis suppression is maintained without compromising growth outcomes. Future prospective studies may further refine monitoring intervals for patients on long-acting preparations, potentially streamlining the management of CPP even further.
References
1. Varughese R, Lake L, Kothayan B, et al. Efficacy of 24-Weekly Versus 12-Weekly Decapeptyl SR Treatment in Central Precocious Puberty: A UK Multicentre Retrospective Cohort Study. The Journal of Clinical Endocrinology and Metabolism. 2026. PMID: 41793064.
2. Carel JC, Eugster EA, Rogol A, et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics. 2009;123(4):e752-e762.
3. Latronico AC, Brito VN, Carel JC. Causes, diagnosis, and treatment of central precocious puberty. The Lancet Diabetes & Endocrinology. 2016;4(3):265-274.
